First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
J. Rodon Ahnert
No relevant relationships to disclose
J. Baselga
No relevant relationships to disclose
E. Calvo
Research Funding - Lilly
J. Seoane
Research Funding - Lilly
I. Brana
No relevant relationships to disclose
E. Sicart
No relevant relationships to disclose
I. Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
A. Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
S. Pillay
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. Holdhoff
No relevant relationships to disclose
J. O. Blakeley
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose